How big is Arcellx, Inc.?

As of Jun 18, Arcellx, Inc. has a market capitalization of $3.47 billion, with net sales of $76.81 million and a net profit of -$162.42 million over the last four quarters. As of Dec 24, shareholder's funds are $454.79 million and total assets are $711.33 million.

As of Jun 18, Arcellx, Inc. has a market capitalization of 3,465.11 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 76.81 million, while the sum of net profit for the same period is -162.42 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 454.79 million and total assets at 711.33 million.

What does Arcellx, Inc. do?

Arcellx, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $8 million and a net loss of $62 million as of March 2025. Key financial metrics include a market cap of $3.47 billion, a P/E ratio of NA, and a dividend yield of 0%.

Overview:<BR>Arcellx, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -62 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3,465.11 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.29 <BR>Return on Equity: -38.96% <BR>Price to Book: 8.31 <BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Arcellx, Inc.?

Is Arcellx, Inc. overvalued or undervalued?

As of May 8, 2023, Arcellx, Inc. is considered risky and overvalued due to its high Price to Book Value of 9.00, negative EV to EBIT of -16.87, and troubling ROE of -38.96%, despite showing strong short-term performance compared to the S&P 500.

As of 8 May 2023, the valuation grade for Arcellx, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its high Price to Book Value of 9.00, a negative EV to EBIT of -16.87, and a troubling ROE of -38.96%. In comparison to its peers, Arcellx's EV to EBITDA of -17.41 is less favorable than Arrowhead Pharmaceuticals, which stands at -40.56, but significantly worse than Alvotech's 39.96.<BR><BR>Despite the overvaluation, Arcellx has shown strong short-term performance with a 1-week return of 2.96% compared to the S&P 500's 1.05%, and a 1-month return of 11.36% against 2.33% for the index. However, its year-to-date return of 4.29% lags behind the S&P 500's 12.22%, and its 1-year return of -0.71% is notably underwhelming compared to the S&P's 17.14%. Overall, the company's financial metrics and performance suggest it is overvalued in the current market context.

Is Arcellx, Inc. technically bullish or bearish?

As of September 4, 2025, Arcellx, Inc. shows a bullish technical trend supported by positive indicators like the weekly MACD, Bollinger Bands, and KST, along with outperforming the S&P 500 in recent weeks.

As of 4 September 2025, the technical trend for Arcellx, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, supporting the positive stance. Daily moving averages also indicate a bullish trend. The KST is bullish on both weekly and monthly time frames, while Dow Theory shows a mildly bullish signal on both weekly and monthly as well. The stock has outperformed the S&P 500 over the past week and month, with returns of 2.96% and 11.36% compared to 1.05% and 2.33% for the index, respectively. Overall, the current technical stance is bullish with strong indicators supporting this view.